Brandtree

Who owns Feitas?

Feitas is owned by Hisamitsu Pharmaceutical (Japan, TSE: 4530).[1]

This ownership is reported in official statements but has not yet been matched to a regulatory filing.

Evidence: Hisamitsu Pharmaceutical Group Integrated Report 2025, Hisamitsu Pharmaceutical Co., Inc. Last checked .

Key facts

Current owner
Hisamitsu Pharmaceutical Co., Inc. reported
Owner HQ
🇯🇵 Japan
Origin
🇯🇵 Japan
Founded
2003
Category
Consumer health › Over-the-counter medicine › Pain relief
Parent ticker
TSE: 4530
Last verified
· 1 sources

About Feitas

Feitas is a Hisamitsu pain-relief patch brand that the company's integrated report lists among its major products as launched in 2003. The report says overseas sales of Feitas rose 346.1 per cent over the HX2025 medium-term plan period, and treats it alongside Salonpas and ByeBye-Fever as one of the over-the-counter growth products.

Ownership timeline of Feitas

Owners of Feitas over 2003 to 2026 Hisamitsu Pharmaceutical start not recorded–present Hisamitsu Pharmaceutical (start not recorded) 20052010201520202025
  1. Current owner Hisamitsu Pharmaceutical [1] reported

Where Feitas sits in Hisamitsu Pharmaceutical

Controlling ownership as of . Brands grouped under the entity that owns them; large groups are collapsed.

Where Feitas sits in Hisamitsu Pharmaceutical Tree of 3 brands under Hisamitsu Pharmaceutical. Hisamitsu Pharmaceutical Feitas Air Salonpas Salonpas

Open the full Hisamitsu Pharmaceutical ownership tree →

See the full Hisamitsu Pharmaceutical brand portfolio (3) →

Other brands owned by Hisamitsu Pharmaceutical

Hisamitsu Pharmaceutical controls 3 brands on Brandtree, 3 of them in consumer health.

Also in consumer health

All Hisamitsu Pharmaceutical brands →

Other brands in pain relief, and who owns them

The 34 brands in pain relief on Brandtree belong to 19 owners. The largest is Haleon, with 3; Hisamitsu Pharmaceutical has 3.

BrandOwnerOwner based in
Advil Haleon 🇬🇧 United Kingdom
Motrin Kenvue 🇺🇸 United States
Dafalgan Taisho Pharmaceutical 🇯🇵 Japan
Mentho Plus Emami 🇮🇳 India
Bufferin (United States) Genomma Lab 🇲🇽 Mexico
Doril Hypera 🇧🇷 Brazil
Daleron Krka 🇸🇮 Slovenia
Kunyit Asam Sido Muncul Sido Muncul 🇮🇩 Indonesia

Every brand in pain relief and its owner →

About the owner: Hisamitsu Pharmaceutical

Hisamitsu Pharmaceutical is a publicly listed company headquartered in Japan, founded in 1847. Brandtree records 3 brands under its control, and it is listed as TSE: 4530.

Hisamitsu Pharmaceutical is a Japanese drug maker, listed in Tokyo, built around transdermal patches. Its integrated report gives the founding year as 1847, with head offices in Kyushu (main) and Tokyo, and traces its patch business to Asahi Mankinko in 1907. It also sells prescription patches through Noven Pharmaceuticals in the United States. Only its over-the-counter pain-relief brands are recorded here.

Hisamitsu Pharmaceutical: full profile, brands and acquisition history →

🇯🇵 Feitas and other Japanese brands

Brandtree records a controlling owner for 437 brands that began in Japan. 21 of them (5%) are now controlled by a company headquartered in another country; Feitas is not one of them.

All Japanese brands and who owns them →

Frequently asked questions

Who is the parent company of Feitas?

The parent company of Feitas is Hisamitsu Pharmaceutical, a publicly listed company headquartered in Japan.

Is Feitas Japanese?

Yes. Feitas originated in Japan in 2003 and its owner, Hisamitsu Pharmaceutical, is also headquartered in Japan.

Is Feitas still owned by Hisamitsu Pharmaceutical?

Yes. As of 3 October 2026, Feitas is still owned by Hisamitsu Pharmaceutical. The ownership record was last checked against primary sources on that date.

Sources (1) & corrections

Last verified . Every ownership fact above is backed by one of these primary documents. Numbers in brackets in the text refer to this list.

  1. [1] Hisamitsu Pharmaceutical Group Integrated Report 2025 — Hisamitsu Pharmaceutical Co., Inc., Annual report; retrieved 3 October 2026.

Report a correction Opens a pre-filled GitHub issue. See our corrections policy.